Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence

Brian Godman, Amanj Kurdi, Holly McCabe, Chris F Johnson, Corrado Barbui, Sean MacBride-Stewart, Simon Hurding, Axel Leporowski, Marion Bennie, Alec Morton

Research output: Contribution to journalArticle

Abstract

Aim: Increasing use of selective serotonin-reuptake inhibitors (SSRIs) in Scotland, coupled with safety concerns with some SSRIs, and the increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and efficiency of their prescribing in Scotland. Our aim is to assess their influence to provide future direction. Materials & methods: The prescription costs analysis database was used to document utilization and expenditure on SSRIs between 2001 and 2017 alongside documenting the initiatives. Results: Multiple interventions over the years increased international nonproprietary name prescribing up to 99.9% lowering overall costs. This, coupled with initiatives to limit escitalopram prescribing due to concerns with its value, resulted in a 73.7% reduction in SSRI expenditure between 2001 and 2017 despite a 2.34-fold increase in utilization. Safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline Conclusion: Multiple initiatives have increased the quality and efficiency of SSRI prescribing in Scotland providing direction to others.

LanguageEnglish
Pages535-547
Number of pages13
JournalJournal of Comparative Effectiveness Research
Volume8
Issue number7
Early online date26 Apr 2019
DOIs
Publication statusPublished - 1 May 2019

Fingerprint

Serotonin Uptake Inhibitors
National Health Programs
Health
Citalopram
Scotland
Health Expenditures
Safety
Costs and Cost Analysis
Sertraline
Paroxetine
Names
Prescriptions
Costs
Availability
Databases

Keywords

  • SSRIs
  • Scottish NHS
  • expenditure
  • drug utlisation
  • generics
  • healthcare reform

Cite this

@article{039c6fc56cc841f1bf93027d701803ca,
title = "Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence",
abstract = "Aim: Increasing use of selective serotonin-reuptake inhibitors (SSRIs) in Scotland, coupled with safety concerns with some SSRIs, and the increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and efficiency of their prescribing in Scotland. Our aim is to assess their influence to provide future direction. Materials & methods: The prescription costs analysis database was used to document utilization and expenditure on SSRIs between 2001 and 2017 alongside documenting the initiatives. Results: Multiple interventions over the years increased international nonproprietary name prescribing up to 99.9{\%} lowering overall costs. This, coupled with initiatives to limit escitalopram prescribing due to concerns with its value, resulted in a 73.7{\%} reduction in SSRI expenditure between 2001 and 2017 despite a 2.34-fold increase in utilization. Safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline Conclusion: Multiple initiatives have increased the quality and efficiency of SSRI prescribing in Scotland providing direction to others.",
keywords = "SSRIs, Scottish NHS, expenditure, drug utlisation, generics, healthcare reform",
author = "Brian Godman and Amanj Kurdi and Holly McCabe and Johnson, {Chris F} and Corrado Barbui and Sean MacBride-Stewart and Simon Hurding and Axel Leporowski and Marion Bennie and Alec Morton",
year = "2019",
month = "5",
day = "1",
doi = "10.2217/cer-2018-0132",
language = "English",
volume = "8",
pages = "535--547",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6313",
number = "7",

}

Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. / Godman, Brian; Kurdi, Amanj; McCabe, Holly; Johnson, Chris F; Barbui, Corrado; MacBride-Stewart, Sean; Hurding, Simon; Leporowski, Axel; Bennie, Marion; Morton, Alec.

In: Journal of Comparative Effectiveness Research, Vol. 8, No. 7, 01.05.2019, p. 535-547.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence

AU - Godman, Brian

AU - Kurdi, Amanj

AU - McCabe, Holly

AU - Johnson, Chris F

AU - Barbui, Corrado

AU - MacBride-Stewart, Sean

AU - Hurding, Simon

AU - Leporowski, Axel

AU - Bennie, Marion

AU - Morton, Alec

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Aim: Increasing use of selective serotonin-reuptake inhibitors (SSRIs) in Scotland, coupled with safety concerns with some SSRIs, and the increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and efficiency of their prescribing in Scotland. Our aim is to assess their influence to provide future direction. Materials & methods: The prescription costs analysis database was used to document utilization and expenditure on SSRIs between 2001 and 2017 alongside documenting the initiatives. Results: Multiple interventions over the years increased international nonproprietary name prescribing up to 99.9% lowering overall costs. This, coupled with initiatives to limit escitalopram prescribing due to concerns with its value, resulted in a 73.7% reduction in SSRI expenditure between 2001 and 2017 despite a 2.34-fold increase in utilization. Safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline Conclusion: Multiple initiatives have increased the quality and efficiency of SSRI prescribing in Scotland providing direction to others.

AB - Aim: Increasing use of selective serotonin-reuptake inhibitors (SSRIs) in Scotland, coupled with safety concerns with some SSRIs, and the increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and efficiency of their prescribing in Scotland. Our aim is to assess their influence to provide future direction. Materials & methods: The prescription costs analysis database was used to document utilization and expenditure on SSRIs between 2001 and 2017 alongside documenting the initiatives. Results: Multiple interventions over the years increased international nonproprietary name prescribing up to 99.9% lowering overall costs. This, coupled with initiatives to limit escitalopram prescribing due to concerns with its value, resulted in a 73.7% reduction in SSRI expenditure between 2001 and 2017 despite a 2.34-fold increase in utilization. Safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline Conclusion: Multiple initiatives have increased the quality and efficiency of SSRI prescribing in Scotland providing direction to others.

KW - SSRIs

KW - Scottish NHS

KW - expenditure

KW - drug utlisation

KW - generics

KW - healthcare reform

U2 - 10.2217/cer-2018-0132

DO - 10.2217/cer-2018-0132

M3 - Article

VL - 8

SP - 535

EP - 547

JO - Journal of Comparative Effectiveness Research

T2 - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6313

IS - 7

ER -